Effect of Anti-HB transfer factor and Adefovir Combination Therapy on Patients with Chronic-Hepatitis B and Influence on HBV DNA

Zhu YuJia

Issue 5

May 2008

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2008 > 24(5): 338-340

PDF( 168 KB)

阿德福韦酯联合抗乙型肝炎转移因子对慢性乙型肝炎的治疗研究

Zhu YuJia

Published Date: 2008-05-20

Abstract

Abstract

Objective To observe the effect of combined application of anti-HB transfer factor and Adefovir in treating patients with chronic hepatitis B (CHB) and its influence on HBV DNA.Methods 184 patients were enrolled and randomized into two groups: the treated grorp (92 cases) and control group (92cases) .The treated group received anti-HB transfer factor and Adefovir simultaneously for 12 months.The control group received Adefovir alone for 12 months Liver function, virological parameters, serum HBV DNA and HBV DNA were evaluated.Liver biopsy was taken before therapy and after 12 months treament in 40patients.Results After 12months treatment, there was no difference in HBV DNA negative rate between treated group and control groups (P>0.05) .Most of liver histology were improved in 40 patients.Conclusions Combined application of anti-HB transfer factor and 1 Adefovir could enhance the therapeutic effect in treating CHB to certain extent, but effect on HBV DNA should be study further more.
- Chronic hepatitis B,
- HBV DNA,
- Adefovir,
- anti-HBV transfer factor

FullText(HTML)

References(10)

References

[1]中华医学会.病毒性肝炎防治方案[J].中华肝脏病杂志, 2000, 8 (6) ∶324~329.

[2]GUO Y, GUO H, ZHANG L, et al.Genomic analysis of anti-hep-atitis B virus (HBV) activity by small instble HBV-producingcells[J].J Virol, 2005, 79 (220∶14392-14403.

[3]BENHAMOUY.Treatment algorithm for chronic hepatitis B in HIV-infected patients[J].J Hepatol, 2006, 44 (1 Suppl) ∶S90-S94.

[4]Wolters LM, Niesters HG, de Man RA, et al.Nucleoside analoguesfor chronic hepatitis B[J].Eur J Gastroenterol Hepatol, 2001, 13 (12) ∶1499-1506.

[5]蒋晔, 徐智儒, 张晓青.抗乙肝新药阿德福韦酯的研究进展[J].中国新药与临床杂志, 2004, 23 (6) ∶373-377.

[6]Hadziyannis SJ, Tassopoulos NS, Heathcote EJ, et al.Adefovir dip-ivoxil for the treatment of hepatitis B e antigen-negative chronichepatitis B[J].N Engl J Med, 2003, 348∶800-807.

[7]Marcellin P, Chang TT, Lim SG, et al.Adefovir dipivoxil for hetreatment of hepatitis B e antigen-positive chronic hepatitis B[J].NEngl J Med, 2003, 348∶808-816.

[8]Hadziyannis S, Tassopoulos N, Chang TT, et al.three-year studyof adefovir dipivoxil (ADV) demonstrates sustained efficacy in pre-sumed precore mutant chronic hepatitis B patients in a long-termsafety and efficacy study[J].J Hepatol, 2004 (Suppl 1) ∶17 (Ab-stract 46) .

[9]Zoulim F.Assessment of treatment efficacy in HBVinfection and dis-ease[J].J Hepatol, 2006, 44 (1 Suppl) ∶S95~99.

[10]于建国, 倪介萍, 郭葆玉.慢性乙型肝炎抗病毒药物临床应用现状[J].临床军医杂志, 2002, 30 (6) ∶80~82.

Relative Articles

[1]	LIN Yan, ZHANG YueRong, WANG Hui, ZHANG YaoDi, WU LiYang, WEI ShiFang, LI XiangLin, MA YanYun, WANG ChunXia. Value of highly sensitive nucleic acid detection and aminotransferase level in evaluating precise antiviral therapy for liver cirrhosis patients with a low viral load[J]. Journal of Clinical Hepatology, 2020, 36(11): 2446-2449. doi: 10.3969/j.issn.1001-5256.2020.11.010
[2]	Wu XiaoNing, Zhang Wei, Zhou JiaLing, Wang Lin, Sun YaMeng, Meng TongTong, Wang XiaoMing, You Hong, Ou XiaoJuan, Jia JiDong. Influence of baseline HBV DNA level on the clinical outcome of patients with compensated hepatitis B cirrhosis after antiviral therapy[J]. Journal of Clinical Hepatology, 2018, 34(8): 1678-1682. doi: 10.3969/j.issn.1001-5256.2018.08.017
[3]	Li Na, Gou Wei, Cui WeiLi. Efficacy of telbivudine combined with adefovir dipivoxil and pegylated interferon combined with entecavir as antiviral therapy for chronic hepatitis B: a comparative analysis[J]. Journal of Clinical Hepatology, 2016, 32(9): 1714-1716. doi: 10.3969/j.issn.1001-5256.2016.09.015
[4]	Yang XiaoYan, Sun ZhangYu, Yuan Xiang, Liang YaLin. Clinical analysis of hypophosphatemia induced by adefovir dipivoxil in treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(12): 2047-2050. doi: 10.3969/j.issn.1001-5256.2015.12.014
[5]	Zhou LianLian, Shen Mo, Zhou Ping, Zhou Wu, Lin XiangYang. HBV genotype distribution and its relationship with serum HBV DNA level and HBeAg expression among patients with chronic hepatitis B in southern Zhejiang Province, China[J]. Journal of Clinical Hepatology, 2014, 30(10): 1039-1041. doi: 10.3969/j.issn.1001-5256.2014.10.016
[6]	Ruan BingWei, Lu XiaoJu, Lin YanMing, Chen RongCe, Chen XinZhi, Ceng GuangZhong, Liu YanPing. Evaluation of adverse reactions induced by adefovir dipivoxil in 85 chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2013, 29(2): 104-106.
[7]	Li Juan, Tian Jie, Han Tao, Wei Su. Chronic hepatitis B with adefovir-associated renal insufficiency: a case report[J]. Journal of Clinical Hepatology, 2012, 28(12): 956-957.
[8]	Wang LiPing, Han FangZheng, Li ChunYang, Yan Mei, Zhang YanChao, Yan XueBing. Evaluation of adefovir primary resistance and adefovir repulsive mutations of the HBV DNA P gene in chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2012, 28(8): 606-608.
[9]	Qiu YingFeng, Ding YongGang, Li GuangMing. Analysis of therapeutic effect of adefovir dipivoxil in continued treatment of chronic hepatitis B patients with poor early virological response to initial treatment[J]. Journal of Clinical Hepatology, 2011, 27(6): 611-613.
[10]	Liu LongGen, Ye ChunYan, Tong XueCheng. Maintenance of negative HBV DNA in patients with chronic hepatitis B during 96 weeks followup with active replacement of Adefovir dipivoxil with Lamivudine[J]. Journal of Clinical Hepatology, 2011, 27(3): 292-294.
[11]	Yang YaFang, Yang XiaoPing, Dong JianGuo, Wang ZhiGang, Liu YanPing, Zhao TieJun, Gao Feng. Analysis of short-term efficacy of entecavir and adefovir dipivoxil in the treatment of HBeAg-positive chronic hepatitis B [J]. Journal of Clinical Hepatology, 2010, 26(3): 326-327.
[12]	Luo FangQiong, Pan Yu, Liu JingJing, Zhang Peng, Niu JunQi, Jiang YanFang. The Impact of Adefovior dipivoxil on Th1/Th2 cytokines in chronic hepatitis B Patients[J]. Journal of Clinical Hepatology, 2010, 26(1): 19-21.
[14]	Yuan HaiNing, Luo GuangHan, Deng YiMing. Effect of combination treatment of Adefovir and r-IFN to the hepatic fibrosis caused by hepatitis B[J]. Journal of Clinical Hepatology, 2008, 24(4): 254-255.
[16]	Cao TianGao, Li JingNan, Shi YunZhen, Li ChaoXia. The clinical study of foscarnet sodium combined with adefovir dipivoxil for lamivudine-resistant patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2008, 24(4): 248-250.
[18]	Wang Yuan, Yu LiangKe, Cao KeYong, Zhang RuiFeng, Zhang YuZhong. The efficacy of HBeAg-positive chronic hepatitis B with Adefovir dipivoxil and Ganluoxin pills in 24 weeks[J]. Journal of Clinical Hepatology, 2007, 23(6): 428-429.
[19]	Liu ChengYong, Hou YuanPei, Qian XiuMei, Sun Qing, Song Li. Distribution of hepatitis B virus genotype in Xuzhou and its clinical significance[J]. Journal of Clinical Hepatology, 2005, 21(3): 151-152.
[20]	Xu QingTian, Wu YanXia, Liu ChunLi, Cui ZhongFeng, Li XinYue, Xiong FeiSheng. Relationship between clinics and the content of serum HBV DNA in different clinical types of chronic hepatitis B.[J]. Journal of Clinical Hepatology, 2004, 20(6): 343-344.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2318) PDF downloads(798)

阿德福韦酯联合抗乙型肝炎转移因子对慢性乙型肝炎的治疗研究

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

阿德福韦酯联合抗乙型肝炎转移因子对慢性乙型肝炎的治疗研究

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content